CMRA — Comera Life Sciences Holdings Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$1.76m
- $0.63m
Annual income statement for Comera Life Sciences Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0.443 | 0.32 | 0.633 |
| Cost of Revenue | |||
| Gross Profit | 0.339 | 0.159 | 0.423 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 2.57 | 5.69 | 19.2 |
| Operating Profit | -2.13 | -5.38 | -18.5 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -2.13 | -5.45 | -18 |
| Net Income After Taxes | -2.13 | -5.45 | -18 |
| Net Income Before Extraordinary Items | |||
| Net Income | -2.13 | -5.45 | -18 |
| Adjustments to Net Income | |||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -2.13 | -5.45 | -18.4 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.111 | -0.294 | -1.13 |
| Dividends per Share |